secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOREGENX, INC. (BRGX)
CIK:        0001593184
Form:       8-K/A
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001683168-24-007019
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 2.01, 3.02, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRegenx completes reverse merger; posts $3.6M net loss in 2023 with going concern doubt
--------------------------------------------------------------------------------

- Merger effective March 8, 2024: BioRegenx merged into Findit; registrant renamed BioRegenx, Inc.
- Exchanged 851.98M shares and 3,800 Series A preferred for 90% voting control; retired prior preferred and 172.2M common shares.
- Audited 2023 results: net loss $3.6M, sales $3.41M, stockholders' deficit $2.07M; auditor flags going concern.
- New leadership: William Resides CEO/Interim CFO; new board of 7 directors appointed (8 total including Thomas Powers).
- Authorized common increased to 1.5B shares; Series A preferred voting rights corrected to 2,500 votes per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593184/000168316824007019/0001683168-24-007019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593184/000168316824007019/bioregenx_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer